Reversal of target-specific oral anticoagulants

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 2, 2013, Pages 195-202

  Kaatz, Scott ^a   Crowther, Mark ^b,c,d  

^a HURLEY MEDICAL CENTER   (United States)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Apixaban; Dabigatran; Reversal; Rivaroxaban; Target specific oral anticoagulants

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9 COMPLEX; COFACT; DABIGATRAN; FRESH FROZEN PLASMA; KANOKAD; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; BLEEDING; BLEEDING TIME; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EX VIVO STUDY; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOPERFUSION; HEMOPHILIA; HEMOPHILIA A; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOSIS; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; DRUG DELIVERY SYSTEM; DRUG MONITORING; HEMORRHAGE; MEDICAL EDUCATION; ORAL DRUG ADMINISTRATION; PROCEDURES; STANDARDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG DELIVERY SYSTEMS; DRUG MONITORING; EDUCATION, MEDICAL, CONTINUING; HEMORRHAGE; HUMANS;

EID: 84881478407     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0923-y     Document Type: Review

References (29)

1. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429-438. doi: 10.1160/TH11-01-0052
2. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363(19):1791-1800. doi: 10.1056/NEJMoa1006221
3. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295
4. van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Singh S, Park J (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57(14):E1130
5. Lu G, Luan P, Hollenbach S, Abe K, DeGuzman F, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2009) Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 7(Suppl 2):107
6. Crowther MA, Warkentin TE (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7(Suppl 1):107-110. doi: 10.1111/j.1538-7836.2009.03429.x
7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573-1579. doi: 10.1161/CIRCULATIONAHA.111.029017
8. Perzborn E, Tinel H (2009) Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost 7(suppl 2):379
9. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME (2010) Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 116(5):693-701. doi: 10.1182/blood-2009-11-253492
10. van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 114(22):440
11. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259-268. doi: 10.2165/11318170-000000000-00000
12. Wagner F, Peters H, Formella S, Wiegert E, Moschetti V, Khadzhynov D, Clemens A (2011) Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease. Circulation 124(21 Suppl):A10956
13. Van Ryn J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, Priepke H, Clemens A (2010) Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematologica 95:293
14. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594-3599. doi: 10.1161/STROKEAHA.111.624650
15. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W (2008) Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor viia or activated prothrombin complex concentrate. Haematologica 93:148
16. van Ryn J, Schurer J, Kink-Eiband M, Clemens A (2011) The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 118(21):1004
17. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield W (2012) Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but not dabigatran etexilate. Transfusion 52:56A-57A
18. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217-224. doi: 10.1160/TH12-03-0179
19. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10(9):1841-1848. doi: 10.1111/j.1538-7836.2012.04859.x
20. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S (2012) The use of FEIBA(®) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. doi: 10.1111/ijlh.12005
21. Johnson & Johnson Pharmaceutical Research & Development LLC (2009) Advisory Committee briefing book: rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in Patients undergoing hip or knee replacement surgery. Johnson & Johnson Pharmaceutical Research & Development, L.L.C, San Diego
22. PDR.net (2012) http://www.pdr.net/drugpages/productlabeling.aspx?mpcode= 40229000. Accessed 20 Nov 2012
23. Tinel H, Huetter J, Perzborn E (2006) Partial reversal of the anticoagulant effect of high-dose rivaroxaban - an oral, direct factor Xa inhibitor - by recombinant factor VIIa in rats. Blood 108(11):274A
24. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E (2008) Potential of activated prothrombin complex concentrate and activated factor vii to reverse the anticoagulant effects of rivaroxaban in primates. Blood 112(11):1307
25. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94-102. doi: 10.1097/ALN. 0b013e318238c036
26. European Medicines Agency SMH Assessment report for Eliquis (2011) European Medicines Agency, Science Medicines Health, London
27. Escolar GA-RE, Reverter JC, Villalta J, Sanz V, Molina P, Diaz-Ricart M, Galan AM (2012) Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 126(4):2
28. Miyares MA, Davis K (2012) Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 69(17):1473-1484. doi: 10.2146/ajhp110725
29. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141-S145